Jan

2012

Groove Biopharma, Inc.: Series B $6M

Posted in I - Series B, Q - 4Q11, R - NORTH WEST, X - Antiinfective, X - Fibrosis, X - Oncology, X - miRNA, XX - WA

Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Jan

2012

Excelimmune, Inc.: Series C $12M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, X - Oncology, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Jan

2012

Provenance Biopharmaceuticals, Corp.: Series A $8M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Immunology, X - Oncology, XX - MA

Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

Jan

2012

Agios Pharmaceuticals, Inc.: Series C $78M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Metabolism, X - Oncology, XX - MA

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Jan

2012

Acceleron Pharma, Inc.: Series D $30.4M

Posted in I - Series D, Q - 4Q11, R - NORTH EAST, X - Anemia, X - Muscular Dystrophy, X - Oncology, X - Osteoporosis, XX - MA

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Jan

2012

AuraSense Therapeutics, LLC: Series B $5.4M

Posted in I - Series B, Q - 4Q11, R - MID WEST, X - Cardiology, X - Dermatology, X - Neurology, X - Oncology, XX - IL

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

Jan

2012

Cerulean Pharma, Inc.: Series D $15M

Posted in I - Series D, Q - 4Q11, R - NORTH EAST, X - Oncology, XX - MA

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.

Jan

2012

arGEN-X, BV: Series B $37M

Posted in I - Series B, Q - 4Q11, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Inflammation, X - Oncology, X - Therapeutic Platform

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Jan

2012

Karyopharm Therapeutics, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Inflammation, X - Oncology, XX - MA

Karyopharm Therapeutics (Natick, MA) a preclinical-stage small molecule company focusing on the treatment of cancer and inflammation, closed a $10M Series A financing, bringing the total round to $30M. Participants include Chione.

Jan

2012

Antisense Pharma, GmbH: Series F $11M

Posted in I - Series F, Q - 3Q11, R - INTERNATIONAL, X - Antisense, X - Gene Silencing, X - Oncology

Antisense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $11M Series F financing. Participants include MIG Fonds and Global Asset Fund.
Thanx for your patience as we catch-up.

Jan

2012

Intervention Insights, Inc.: Series B $7.2M

Posted in I - Series B, Q - 3Q11, R - MID WEST, X - Device (Diagnostic), X - Oncology, XX - MI

Intervention Insights (Grand Rapids, MI) a commercial-stage personalized medicine company focused on molecularly targeted oncology therapies, closed a $7.2M Series B financing. Participants include Beringea, Chrysalis Ventures, Hopen Life Science Ventures and Michigan Accelerator Fund.
Thanx for your patience as we catch-up.

Jan

2012

Verastem, Inc.: Series B $32M

Posted in I - Series B, Q - 3Q11, R - NORTH EAST, X - Oncology, X - Stem Cell, XX - MA

Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.
Thanx for your patience as we catch-up.

Jan

2012

Ceptaris Therapeutics, Inc.: Series D $14.4M

Posted in I - Series D, Q - 3Q11, R - NORTH EAST, X - Oncology, XX - PA

Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners.
Thanx for your patience as we catch-up.

« Previous Entries

to top of page...